JAMA study reports drug-induced lupus erythematosus in users of proton pump inhibitors
France: In case of suspected cases of drug-induced lupus erythematosus (DILE), proton pump inhibitors (PPIs) should be considered as a potential etiology, researchers suggest in a study published as a research letter in the journal JAMA Dermatology.
Proton pump inhibitors (PPIs) are medications that exhibit their action by reducing the amount of stomach acid made by glands present in the linings of the stomach. PPIs role has been suggested in the occurrence of drug-induced lupus erythematosus for both drug-induced cutaneous lupus erythematosus (DI-CLE) and drug-induced systemic lupus erythematosus (DI-SLE) but remains poorly characterized.
Considering the above, Pauline Bataille, Hôpital Tenon, Paris, France, and colleagues aimed to examine the pharmacovigilance signal of PPI-associated DILE using different indicator tools for disproportionate reporting. They also strived to better characterize the spectrum of PPI-associated DILE by focusing on the DILE type as well as therapeutic management.
To achieve their objectives, the researchers performed a disproportionality study. They used data from VigiBase, the global pharmacovigilance database of WHO. Case-non-case studies was conducted for all PPIs and each molecule to test potential pharmacovigilance signals in reporting odds rations (RORs) and computing the information. For cases published after r January 1, 2002 sensitivity analyses was performed. The researchers took into account immunological, clinical, and therapeutic management of potential PPI-associated DILE from the French pharmacovigilance database. By using both the DILE types and therapeutic management, the authors aimed to better characterize the spectrum of PPI-associated DILE.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.